Antibody-mediated rejection: prevention, monitoring and treatment dilemmas.

ABSTRACT:

Purpose of review

Antibody-mediated rejection (AMR) has emerged as the leading cause of late graft loss in kidney transplant recipients. Donor-specific antibodies are an independent risk factor for AMR and graft loss. However, not all donor-specific antibodies are pathogenic. AMR treatment is heterogeneous due to the lack of robust trials to support clinical decisions. This review provides an overview and comments on practical but relevant dilemmas physicians experience in managing kidney transplant recipients with AMR.

Recent findings

Active AMR with donor-specific antibodies may be treated with plasmapheresis, intravenous immunoglobulin and corticosteroids with additional therapies considered on a case-by-case basis. On the contrary, no treatment has been shown to be effec

SUBMITTER: Rodriguez-Ramirez S 

PROVIDER: S-EPMC9475491 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature